The FDA approved Wegovy (semaglutide 2.4 mg) for adults with noncirrhotic MASH with moderate to advanced liver fibrosis. Related reporting shows once-weekly semaglutide significantly improved steatohepatitis and fibrosis over 72 weeks. This marks a major expansion of GLP-1 therapy into liver disease treatment.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.